{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "c79f5863-646d-4d45-baab-d17aaf6c303a",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "os.environ['OPENAI_API_KEY']='place your open_ai_api key'\n"
   ]
  },
  {
   "cell_type": "raw",
   "id": "ba7acfca-9d4a-4b9b-8d95-2a2d6f588922",
   "metadata": {},
   "source": [
    "RAG IS AN LLM-MODEL WHICH USES THE CROMADB(VECTORS)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "8d38c1fe-9e77-4435-9ba8-7d0725de6b09",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting chromadb\n",
      "  Using cached chromadb-0.5.5-py3-none-any.whl.metadata (6.8 kB)\n",
      "Collecting build>=1.0.3 (from chromadb)\n",
      "  Using cached build-1.2.2-py3-none-any.whl.metadata (6.2 kB)\n",
      "Requirement already satisfied: pydantic>=1.9 in d:\\anaconda\\lib\\site-packages (from chromadb) (2.9.1)\n",
      "Collecting chroma-hnswlib==0.7.6 (from chromadb)\n",
      "  Using cached chroma_hnswlib-0.7.6.tar.gz (32 kB)\n",
      "  Installing build dependencies: started\n",
      "  Installing build dependencies: finished with status 'done'\n",
      "  Getting requirements to build wheel: started\n",
      "  Getting requirements to build wheel: finished with status 'done'\n",
      "  Preparing metadata (pyproject.toml): started\n",
      "  Preparing metadata (pyproject.toml): finished with status 'done'\n",
      "Collecting fastapi>=0.95.2 (from chromadb)\n",
      "  Using cached fastapi-0.114.2-py3-none-any.whl.metadata (27 kB)\n",
      "Collecting uvicorn>=0.18.3 (from uvicorn[standard]>=0.18.3->chromadb)\n",
      "  Using cached uvicorn-0.30.6-py3-none-any.whl.metadata (6.6 kB)\n",
      "Requirement already satisfied: numpy<2.0.0,>=1.22.5 in d:\\anaconda\\lib\\site-packages (from chromadb) (1.26.4)\n",
      "Collecting posthog>=2.4.0 (from chromadb)\n",
      "  Using cached posthog-3.6.6-py2.py3-none-any.whl.metadata (2.0 kB)\n",
      "Requirement already satisfied: typing-extensions>=4.5.0 in d:\\anaconda\\lib\\site-packages (from chromadb) (4.11.0)\n",
      "Collecting onnxruntime>=1.14.1 (from chromadb)\n",
      "  Using cached onnxruntime-1.19.2-cp312-cp312-win_amd64.whl.metadata (4.7 kB)\n",
      "Collecting opentelemetry-api>=1.2.0 (from chromadb)\n",
      "  Using cached opentelemetry_api-1.27.0-py3-none-any.whl.metadata (1.4 kB)\n",
      "Collecting opentelemetry-exporter-otlp-proto-grpc>=1.2.0 (from chromadb)\n",
      "  Using cached opentelemetry_exporter_otlp_proto_grpc-1.27.0-py3-none-any.whl.metadata (2.3 kB)\n",
      "Collecting opentelemetry-instrumentation-fastapi>=0.41b0 (from chromadb)\n",
      "  Using cached opentelemetry_instrumentation_fastapi-0.48b0-py3-none-any.whl.metadata (2.1 kB)\n",
      "Collecting opentelemetry-sdk>=1.2.0 (from chromadb)\n",
      "  Using cached opentelemetry_sdk-1.27.0-py3-none-any.whl.metadata (1.5 kB)\n",
      "Collecting tokenizers>=0.13.2 (from chromadb)\n",
      "  Using cached tokenizers-0.20.0-cp312-none-win_amd64.whl.metadata (6.9 kB)\n",
      "Collecting pypika>=0.48.9 (from chromadb)\n",
      "  Using cached PyPika-0.48.9-py2.py3-none-any.whl\n",
      "Requirement already satisfied: tqdm>=4.65.0 in d:\\anaconda\\lib\\site-packages (from chromadb) (4.66.4)\n",
      "Requirement already satisfied: overrides>=7.3.1 in d:\\anaconda\\lib\\site-packages (from chromadb) (7.4.0)\n",
      "Collecting importlib-resources (from chromadb)\n",
      "  Using cached importlib_resources-6.4.5-py3-none-any.whl.metadata (4.0 kB)\n",
      "Requirement already satisfied: grpcio>=1.58.0 in d:\\anaconda\\lib\\site-packages (from chromadb) (1.65.4)\n",
      "Collecting bcrypt>=4.0.1 (from chromadb)\n",
      "  Using cached bcrypt-4.2.0-cp39-abi3-win_amd64.whl.metadata (9.9 kB)\n",
      "Collecting typer>=0.9.0 (from chromadb)\n",
      "  Using cached typer-0.12.5-py3-none-any.whl.metadata (15 kB)\n",
      "Collecting kubernetes>=28.1.0 (from chromadb)\n",
      "  Using cached kubernetes-30.1.0-py2.py3-none-any.whl.metadata (1.5 kB)\n",
      "Collecting tenacity>=8.2.3 (from chromadb)\n",
      "  Using cached tenacity-9.0.0-py3-none-any.whl.metadata (1.2 kB)\n",
      "Requirement already satisfied: PyYAML>=6.0.0 in d:\\anaconda\\lib\\site-packages (from chromadb) (6.0.1)\n",
      "Collecting mmh3>=4.0.1 (from chromadb)\n",
      "  Using cached mmh3-4.1.0-cp312-cp312-win_amd64.whl.metadata (13 kB)\n",
      "Requirement already satisfied: orjson>=3.9.12 in d:\\anaconda\\lib\\site-packages (from chromadb) (3.10.7)\n",
      "Collecting httpx>=0.27.0 (from chromadb)\n",
      "  Using cached httpx-0.27.2-py3-none-any.whl.metadata (7.1 kB)\n",
      "Requirement already satisfied: packaging>=19.1 in d:\\anaconda\\lib\\site-packages (from build>=1.0.3->chromadb) (23.2)\n",
      "Collecting pyproject_hooks (from build>=1.0.3->chromadb)\n",
      "  Using cached pyproject_hooks-1.1.0-py3-none-any.whl.metadata (1.3 kB)\n",
      "Requirement already satisfied: colorama in d:\\anaconda\\lib\\site-packages (from build>=1.0.3->chromadb) (0.4.6)\n",
      "Collecting starlette<0.39.0,>=0.37.2 (from fastapi>=0.95.2->chromadb)\n",
      "  Using cached starlette-0.38.5-py3-none-any.whl.metadata (6.0 kB)\n",
      "Requirement already satisfied: anyio in d:\\anaconda\\lib\\site-packages (from httpx>=0.27.0->chromadb) (4.2.0)\n",
      "Requirement already satisfied: certifi in d:\\anaconda\\lib\\site-packages (from httpx>=0.27.0->chromadb) (2024.7.4)\n",
      "Requirement already satisfied: httpcore==1.* in d:\\anaconda\\lib\\site-packages (from httpx>=0.27.0->chromadb) (1.0.2)\n",
      "Requirement already satisfied: idna in d:\\anaconda\\lib\\site-packages (from httpx>=0.27.0->chromadb) (3.7)\n",
      "Requirement already satisfied: sniffio in d:\\anaconda\\lib\\site-packages (from httpx>=0.27.0->chromadb) (1.3.0)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in d:\\anaconda\\lib\\site-packages (from httpcore==1.*->httpx>=0.27.0->chromadb) (0.14.0)\n",
      "Requirement already satisfied: six>=1.9.0 in d:\\anaconda\\lib\\site-packages (from kubernetes>=28.1.0->chromadb) (1.16.0)\n",
      "Requirement already satisfied: python-dateutil>=2.5.3 in d:\\anaconda\\lib\\site-packages (from kubernetes>=28.1.0->chromadb) (2.9.0.post0)\n",
      "Collecting google-auth>=1.0.1 (from kubernetes>=28.1.0->chromadb)\n",
      "  Using cached google_auth-2.34.0-py2.py3-none-any.whl.metadata (4.7 kB)\n",
      "Requirement already satisfied: websocket-client!=0.40.0,!=0.41.*,!=0.42.*,>=0.32.0 in d:\\anaconda\\lib\\site-packages (from kubernetes>=28.1.0->chromadb) (1.8.0)\n",
      "Requirement already satisfied: requests in d:\\anaconda\\lib\\site-packages (from kubernetes>=28.1.0->chromadb) (2.32.2)\n",
      "Collecting requests-oauthlib (from kubernetes>=28.1.0->chromadb)\n",
      "  Using cached requests_oauthlib-2.0.0-py2.py3-none-any.whl.metadata (11 kB)\n",
      "Collecting oauthlib>=3.2.2 (from kubernetes>=28.1.0->chromadb)\n",
      "  Using cached oauthlib-3.2.2-py3-none-any.whl.metadata (7.5 kB)\n",
      "Requirement already satisfied: urllib3>=1.24.2 in d:\\anaconda\\lib\\site-packages (from kubernetes>=28.1.0->chromadb) (2.2.2)\n",
      "Collecting coloredlogs (from onnxruntime>=1.14.1->chromadb)\n",
      "  Using cached coloredlogs-15.0.1-py2.py3-none-any.whl.metadata (12 kB)\n",
      "Requirement already satisfied: flatbuffers in d:\\anaconda\\lib\\site-packages (from onnxruntime>=1.14.1->chromadb) (24.3.25)\n",
      "Requirement already satisfied: protobuf in d:\\anaconda\\lib\\site-packages (from onnxruntime>=1.14.1->chromadb) (3.20.3)\n",
      "Requirement already satisfied: sympy in d:\\anaconda\\lib\\site-packages (from onnxruntime>=1.14.1->chromadb) (1.12)\n",
      "Collecting deprecated>=1.2.6 (from opentelemetry-api>=1.2.0->chromadb)\n",
      "  Using cached Deprecated-1.2.14-py2.py3-none-any.whl.metadata (5.4 kB)\n",
      "Requirement already satisfied: importlib-metadata<=8.4.0,>=6.0 in d:\\anaconda\\lib\\site-packages (from opentelemetry-api>=1.2.0->chromadb) (7.0.1)\n",
      "Collecting googleapis-common-protos~=1.52 (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb)\n",
      "  Using cached googleapis_common_protos-1.65.0-py2.py3-none-any.whl.metadata (1.5 kB)\n",
      "Collecting opentelemetry-exporter-otlp-proto-common==1.27.0 (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb)\n",
      "  Using cached opentelemetry_exporter_otlp_proto_common-1.27.0-py3-none-any.whl.metadata (1.8 kB)\n",
      "Collecting opentelemetry-proto==1.27.0 (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb)\n",
      "  Using cached opentelemetry_proto-1.27.0-py3-none-any.whl.metadata (2.3 kB)\n",
      "Collecting opentelemetry-instrumentation-asgi==0.48b0 (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb)\n",
      "  Using cached opentelemetry_instrumentation_asgi-0.48b0-py3-none-any.whl.metadata (2.0 kB)\n",
      "Collecting opentelemetry-instrumentation==0.48b0 (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb)\n",
      "  Using cached opentelemetry_instrumentation-0.48b0-py3-none-any.whl.metadata (6.1 kB)\n",
      "Collecting opentelemetry-semantic-conventions==0.48b0 (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb)\n",
      "  Using cached opentelemetry_semantic_conventions-0.48b0-py3-none-any.whl.metadata (2.4 kB)\n",
      "Collecting opentelemetry-util-http==0.48b0 (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb)\n",
      "  Using cached opentelemetry_util_http-0.48b0-py3-none-any.whl.metadata (2.5 kB)\n",
      "Requirement already satisfied: setuptools>=16.0 in d:\\anaconda\\lib\\site-packages (from opentelemetry-instrumentation==0.48b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (69.5.1)\n",
      "Requirement already satisfied: wrapt<2.0.0,>=1.0.0 in d:\\anaconda\\lib\\site-packages (from opentelemetry-instrumentation==0.48b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (1.14.1)\n",
      "Collecting asgiref~=3.0 (from opentelemetry-instrumentation-asgi==0.48b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb)\n",
      "  Using cached asgiref-3.8.1-py3-none-any.whl.metadata (9.3 kB)\n",
      "Collecting monotonic>=1.5 (from posthog>=2.4.0->chromadb)\n",
      "  Using cached monotonic-1.6-py2.py3-none-any.whl.metadata (1.5 kB)\n",
      "Collecting backoff>=1.10.0 (from posthog>=2.4.0->chromadb)\n",
      "  Using cached backoff-2.2.1-py3-none-any.whl.metadata (14 kB)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in d:\\anaconda\\lib\\site-packages (from pydantic>=1.9->chromadb) (0.6.0)\n",
      "Requirement already satisfied: pydantic-core==2.23.3 in d:\\anaconda\\lib\\site-packages (from pydantic>=1.9->chromadb) (2.23.3)\n",
      "Collecting huggingface-hub<1.0,>=0.16.4 (from tokenizers>=0.13.2->chromadb)\n",
      "  Using cached huggingface_hub-0.24.7-py3-none-any.whl.metadata (13 kB)\n",
      "Requirement already satisfied: click>=8.0.0 in d:\\anaconda\\lib\\site-packages (from typer>=0.9.0->chromadb) (8.1.7)\n",
      "Collecting shellingham>=1.3.0 (from typer>=0.9.0->chromadb)\n",
      "  Using cached shellingham-1.5.4-py2.py3-none-any.whl.metadata (3.5 kB)\n",
      "Requirement already satisfied: rich>=10.11.0 in d:\\anaconda\\lib\\site-packages (from typer>=0.9.0->chromadb) (13.3.5)\n",
      "Collecting httptools>=0.5.0 (from uvicorn[standard]>=0.18.3->chromadb)\n",
      "  Using cached httptools-0.6.1-cp312-cp312-win_amd64.whl.metadata (3.7 kB)\n",
      "Requirement already satisfied: python-dotenv>=0.13 in d:\\anaconda\\lib\\site-packages (from uvicorn[standard]>=0.18.3->chromadb) (0.21.0)\n",
      "Collecting watchfiles>=0.13 (from uvicorn[standard]>=0.18.3->chromadb)\n",
      "  Using cached watchfiles-0.24.0-cp312-none-win_amd64.whl.metadata (5.0 kB)\n",
      "Collecting websockets>=10.4 (from uvicorn[standard]>=0.18.3->chromadb)\n",
      "  Using cached websockets-13.0.1-cp312-cp312-win_amd64.whl.metadata (6.9 kB)\n",
      "Requirement already satisfied: cachetools<6.0,>=2.0.0 in d:\\anaconda\\lib\\site-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (5.3.3)\n",
      "Requirement already satisfied: pyasn1-modules>=0.2.1 in d:\\anaconda\\lib\\site-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (0.2.8)\n",
      "Collecting rsa<5,>=3.1.4 (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb)\n",
      "  Using cached rsa-4.9-py3-none-any.whl.metadata (4.2 kB)\n",
      "Requirement already satisfied: filelock in d:\\anaconda\\lib\\site-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers>=0.13.2->chromadb) (3.13.1)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in d:\\anaconda\\lib\\site-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers>=0.13.2->chromadb) (2024.3.1)\n",
      "Requirement already satisfied: zipp>=0.5 in d:\\anaconda\\lib\\site-packages (from importlib-metadata<=8.4.0,>=6.0->opentelemetry-api>=1.2.0->chromadb) (3.17.0)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in d:\\anaconda\\lib\\site-packages (from requests->kubernetes>=28.1.0->chromadb) (2.0.4)\n",
      "Requirement already satisfied: markdown-it-py<3.0.0,>=2.2.0 in d:\\anaconda\\lib\\site-packages (from rich>=10.11.0->typer>=0.9.0->chromadb) (2.2.0)\n",
      "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in d:\\anaconda\\lib\\site-packages (from rich>=10.11.0->typer>=0.9.0->chromadb) (2.15.1)\n",
      "Collecting humanfriendly>=9.1 (from coloredlogs->onnxruntime>=1.14.1->chromadb)\n",
      "  Using cached humanfriendly-10.0-py2.py3-none-any.whl.metadata (9.2 kB)\n",
      "Requirement already satisfied: mpmath>=0.19 in d:\\anaconda\\lib\\site-packages (from sympy->onnxruntime>=1.14.1->chromadb) (1.3.0)\n",
      "Collecting pyreadline3 (from humanfriendly>=9.1->coloredlogs->onnxruntime>=1.14.1->chromadb)\n",
      "  Using cached pyreadline3-3.5.2-py3-none-any.whl.metadata (3.6 kB)\n",
      "Requirement already satisfied: mdurl~=0.1 in d:\\anaconda\\lib\\site-packages (from markdown-it-py<3.0.0,>=2.2.0->rich>=10.11.0->typer>=0.9.0->chromadb) (0.1.0)\n",
      "Requirement already satisfied: pyasn1<0.5.0,>=0.4.6 in d:\\anaconda\\lib\\site-packages (from pyasn1-modules>=0.2.1->google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (0.4.8)\n",
      "Using cached chromadb-0.5.5-py3-none-any.whl (584 kB)\n",
      "Using cached bcrypt-4.2.0-cp39-abi3-win_amd64.whl (151 kB)\n",
      "Using cached build-1.2.2-py3-none-any.whl (22 kB)\n",
      "Using cached fastapi-0.114.2-py3-none-any.whl (94 kB)\n",
      "Using cached httpx-0.27.2-py3-none-any.whl (76 kB)\n",
      "Using cached kubernetes-30.1.0-py2.py3-none-any.whl (1.7 MB)\n",
      "Using cached mmh3-4.1.0-cp312-cp312-win_amd64.whl (31 kB)\n",
      "Using cached onnxruntime-1.19.2-cp312-cp312-win_amd64.whl (11.1 MB)\n",
      "Using cached opentelemetry_api-1.27.0-py3-none-any.whl (63 kB)\n",
      "Using cached opentelemetry_exporter_otlp_proto_grpc-1.27.0-py3-none-any.whl (18 kB)\n",
      "Using cached opentelemetry_exporter_otlp_proto_common-1.27.0-py3-none-any.whl (17 kB)\n",
      "Using cached opentelemetry_proto-1.27.0-py3-none-any.whl (52 kB)\n",
      "Using cached opentelemetry_instrumentation_fastapi-0.48b0-py3-none-any.whl (11 kB)\n",
      "Using cached opentelemetry_instrumentation-0.48b0-py3-none-any.whl (29 kB)\n",
      "Using cached opentelemetry_instrumentation_asgi-0.48b0-py3-none-any.whl (15 kB)\n",
      "Using cached opentelemetry_semantic_conventions-0.48b0-py3-none-any.whl (149 kB)\n",
      "Using cached opentelemetry_util_http-0.48b0-py3-none-any.whl (6.9 kB)\n",
      "Using cached opentelemetry_sdk-1.27.0-py3-none-any.whl (110 kB)\n",
      "Using cached posthog-3.6.6-py2.py3-none-any.whl (54 kB)\n",
      "Using cached tenacity-9.0.0-py3-none-any.whl (28 kB)\n",
      "Using cached tokenizers-0.20.0-cp312-none-win_amd64.whl (2.3 MB)\n",
      "Using cached typer-0.12.5-py3-none-any.whl (47 kB)\n",
      "Using cached uvicorn-0.30.6-py3-none-any.whl (62 kB)\n",
      "Using cached importlib_resources-6.4.5-py3-none-any.whl (36 kB)\n",
      "Using cached backoff-2.2.1-py3-none-any.whl (15 kB)\n",
      "Using cached Deprecated-1.2.14-py2.py3-none-any.whl (9.6 kB)\n",
      "Using cached google_auth-2.34.0-py2.py3-none-any.whl (200 kB)\n",
      "Using cached googleapis_common_protos-1.65.0-py2.py3-none-any.whl (220 kB)\n",
      "Using cached httptools-0.6.1-cp312-cp312-win_amd64.whl (55 kB)\n",
      "Using cached huggingface_hub-0.24.7-py3-none-any.whl (417 kB)\n",
      "Using cached monotonic-1.6-py2.py3-none-any.whl (8.2 kB)\n",
      "Using cached oauthlib-3.2.2-py3-none-any.whl (151 kB)\n",
      "Using cached shellingham-1.5.4-py2.py3-none-any.whl (9.8 kB)\n",
      "Using cached starlette-0.38.5-py3-none-any.whl (71 kB)\n",
      "Using cached watchfiles-0.24.0-cp312-none-win_amd64.whl (277 kB)\n",
      "Using cached websockets-13.0.1-cp312-cp312-win_amd64.whl (152 kB)\n",
      "Using cached coloredlogs-15.0.1-py2.py3-none-any.whl (46 kB)\n",
      "Using cached pyproject_hooks-1.1.0-py3-none-any.whl (9.2 kB)\n",
      "Using cached requests_oauthlib-2.0.0-py2.py3-none-any.whl (24 kB)\n",
      "Using cached asgiref-3.8.1-py3-none-any.whl (23 kB)\n",
      "Using cached humanfriendly-10.0-py2.py3-none-any.whl (86 kB)\n",
      "Using cached rsa-4.9-py3-none-any.whl (34 kB)\n",
      "Using cached pyreadline3-3.5.2-py3-none-any.whl (80 kB)\n",
      "Building wheels for collected packages: chroma-hnswlib\n",
      "  Building wheel for chroma-hnswlib (pyproject.toml): started\n",
      "  Building wheel for chroma-hnswlib (pyproject.toml): finished with status 'error'\n",
      "Failed to build chroma-hnswlib\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  error: subprocess-exited-with-error\n",
      "  \n",
      "  Building wheel for chroma-hnswlib (pyproject.toml) did not run successfully.\n",
      "  exit code: 1\n",
      "  \n",
      "  [5 lines of output]\n",
      "  running bdist_wheel\n",
      "  running build\n",
      "  running build_ext\n",
      "  building 'hnswlib' extension\n",
      "  error: Microsoft Visual C++ 14.0 or greater is required. Get it with \"Microsoft C++ Build Tools\": https://visualstudio.microsoft.com/visual-cpp-build-tools/\n",
      "  [end of output]\n",
      "  \n",
      "  note: This error originates from a subprocess, and is likely not a problem with pip.\n",
      "  ERROR: Failed building wheel for chroma-hnswlib\n",
      "ERROR: Could not build wheels for chroma-hnswlib, which is required to install pyproject.toml-based projects\n"
     ]
    }
   ],
   "source": [
    "!pip install chromadb"
   ]
  },
  {
   "cell_type": "raw",
   "id": "00125665-49ad-41fe-af9e-368ebe3d805f",
   "metadata": {},
   "source": [
    "NOT THAT MUCH NECESSARY  BELOW PACKAGE OR LIBRARY OR METHOD "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "52b898b5-0167-457f-9f93-0af2eb5b1f09",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.text_splitter import CharacterTextSplitter\n",
    "from langchain.vectorstores import Chroma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "6c713ede-27e1-419f-8361-533b1970bbb2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: PyPDF2 in d:\\anaconda\\lib\\site-packages (3.0.1)\n"
     ]
    }
   ],
   "source": [
    "!pip install PyPDF2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "f56fa526-1589-4d3a-822c-034ea7561c53",
   "metadata": {},
   "outputs": [],
   "source": [
    "import PyPDF2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "672e640e-56e6-404c-be50-c0d48000bab0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: pdfplumber in d:\\anaconda\\lib\\site-packages (0.11.4)\n",
      "Requirement already satisfied: pdfminer.six==20231228 in d:\\anaconda\\lib\\site-packages (from pdfplumber) (20231228)\n",
      "Requirement already satisfied: Pillow>=9.1 in d:\\anaconda\\lib\\site-packages (from pdfplumber) (10.3.0)\n",
      "Requirement already satisfied: pypdfium2>=4.18.0 in d:\\anaconda\\lib\\site-packages (from pdfplumber) (4.30.0)\n",
      "Requirement already satisfied: charset-normalizer>=2.0.0 in d:\\anaconda\\lib\\site-packages (from pdfminer.six==20231228->pdfplumber) (2.0.4)\n",
      "Requirement already satisfied: cryptography>=36.0.0 in d:\\anaconda\\lib\\site-packages (from pdfminer.six==20231228->pdfplumber) (42.0.5)\n",
      "Requirement already satisfied: cffi>=1.12 in d:\\anaconda\\lib\\site-packages (from cryptography>=36.0.0->pdfminer.six==20231228->pdfplumber) (1.16.0)\n",
      "Requirement already satisfied: pycparser in d:\\anaconda\\lib\\site-packages (from cffi>=1.12->cryptography>=36.0.0->pdfminer.six==20231228->pdfplumber) (2.21)\n"
     ]
    }
   ],
   "source": [
    "!pip install pdfplumber"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "0ce9e68f-4283-47e3-97b2-1739f9a2173b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk 1:\n",
      "REVIEWS212\n",
      "Clinical aspects of Ebola virus disease: \n",
      "a review\n",
      "Simran Batra1, Rohan Kumar Ochani1, Mufaddal Najmuddin Diwan1, Farah Yasmin1,  \n",
      "Suha Safi Qureshi2, Sameer Bhimani3, Shehryar Shaikh4, Muhammad Ali Tariq4,  \n",
      "Muhammad Ahmed Ashraf2, Hamza Ahmed Farooqi2, Sunil Kumar Dodani5\n",
      "1Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan;  \n",
      "2Department of Internal Medicine, Ziauddin Medical University, Karachi, Pakistan; \n",
      "3Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan; \n",
      "4Department of Internal Medicine, Dow International Medical College, DUHS, Karachi, Pakistan;  \n",
      "5Department of Infectious Diseases, Sindh Institute of Urology and Transplantation, Karachi, Pakistan \n",
      "Ebola Virus Disease (EVD), also known as Ebola \n",
      "Hemorrhagic Fever (EHF), initially emerged over 40 \n",
      "years ago in the Democratic Republic of Congo. En-\n",
      "demic to Africa, outbreaks have been recorded in six \n",
      "African countries since its detection in 1976. Fruit bats \n",
      "are believed to be the natural hosts of Ebola viruses \n",
      "(EBoV), with humans and other mammals serving \n",
      "as accidental hosts. Transmission of EBoV has been \n",
      "reported in various ways, including human to hu-\n",
      "man transmission through close contact with blood \n",
      "and bodily fluids. The virus has an incubation period \n",
      "ranging from two to twenty-one days, followed by a \n",
      "multitude of clinical manifestations such as the sud-\n",
      "den onset of high fever, chills and myalgia depicting \n",
      "a flu-like syndrome. It is usually diagnosed based on \n",
      "several clinical symptoms such as the sudden onset \n",
      "of illness, high fevers for less than three weeks, and \n",
      "at least two hemorrhagic symptoms despite no pre-SUMMARY\n",
      "disposing factors. This generally provides enough ev-\n",
      "idence for clinicians to consider EHF and begin sup-\n",
      "portive treatment until the virus is confirmed through \n",
      "laboratory findings. Management of patients involves \n",
      "supportive care such as maintaining fluid along with \n",
      "electrolyte balance, blood pressure and oxygen sat-\n",
      "uration. This also includes treating complications \n",
      "arising from secondary infections. The main options \n",
      "include: prophylactic strategies, anti-viral therapy for \n",
      "EVD, immunotherapies, vaccines, and ZMapp. Final-\n",
      "ly, the key to managing EBoV epidemics is to stop the \n",
      "transmission of disease in the most severely affected \n",
      "population, as prevention has become of utmost im-\n",
      "portance to alleviate the significant physical and eco-\n",
      "nomic burden. \n",
      "Keywords: Ebola virus; outbreaks; Ebola hemorrhagic \n",
      "fever; filovirus.\n",
      "Corresponding author\n",
      "Simran Batra\n",
      "E-mail: batrasimran674@gmail.comn INTRODUCTION\n",
      "Ebola Virus Disease (EVD), also known as the \n",
      "Ebola Hemorrhagic Fever (EHF), initially \n",
      "emerged in 1976 with a deadly infectious epidem-\n",
      "ic characterized by acute viral hemorrhagic fever. \n",
      "This outbreak constituted of 318 cases and a high \n",
      "mortality rate of 88% (280 deaths) in Yambuku; \n",
      "hence, it was named Ebola after the Ebola River Le Infezioni in Medicina, n. 2, 212-222, 2020\n",
      "in the Democratic Republic of Congo (DRC) [1]. \n",
      "The genus Ebola virus belongs to the family Filo-\n",
      "viridae, along with the genus Marburg virus. This \n",
      "highly virulent virus consists of a characteristic \n",
      "filamentous or branching convoluted shape and \n",
      "is enveloped containing linear non-segmented, \n",
      "negative-sense single-stranded RNA genome [2]. \n",
      "There are five species of this virus, with each sub-\n",
      "type having different biologic characteristics and \n",
      "virulence [2, 3]. Fruit bats belonging to the Pter -\n",
      "opodidae family are thought to be responsible for \n",
      "the dissemination of this zoonotic virus, believed \n",
      "to be the natural hosts of Ebola viruses (EBoV), \n",
      "with humans and other mammals serving as ac-213\n",
      "Clinical aspects of Ebola virus disease: a review\n",
      "cidental hosts [4]. Transmission of the EBoV has \n",
      "been reported in various ways, including human \n",
      "to human transmission through close contact with \n",
      "blood and bodily fluids such as saliva, breast milk, \n",
      "urine and semen from another infected human or \n",
      "animal, either by direct contact or indirectly from \n",
      "contaminated objects like needles and syringes. \n",
      "Moreover, it is not spread through aerosol drop-\n",
      "lets or by water and food contamination [5].\n",
      "Since the original case of this life-threatening \n",
      "disease in DRC, the majority of the outbreaks of \n",
      "EBoV disease have been reported in Africa. The \n",
      "2014-2016 outbreaks emerged in the rural setting \n",
      "of southeastern Guinea which eventually spread \n",
      "to the crowded urban areas and across borders \n",
      "thus becoming a global epidemic. These outbreaks \n",
      "were declared as a Public Health Emergency of \n",
      "International Concern (PHEIC) by World Health \n",
      "Organization (WHO) resulting in more than \n",
      "28,600 cases and 11,325 deaths. Furthermore, due \n",
      "to widespread transmission, countries includ-\n",
      "ing Guinea, Senegal, Nigeria, and United States \n",
      "amongst others were also affected during the ep-\n",
      "idemic [6]. The EBoV has an incubation period \n",
      "ranging from two to twenty-one days, followed \n",
      "by a multitude of clinical manifestations such as \n",
      "the sudden onset of high fever, chills and myalgia \n",
      "depicting a flu-like syndrome [2, 7].\n",
      "In 2018-2019, the tenth and largest EVD outbreak \n",
      "occurred in the DRC since Zaire Ebola virus was \n",
      "first discovered there in 1976. This epidemic in-\n",
      "volved 1600 patients with a case fatality rate of \n",
      "67%. The outbreak was first reported as a clus-\n",
      "ter of cases of acute hemorrhagic fever in North \n",
      "Kivu following which EVD was also detected in \n",
      "Ituri province and important commercial hubs \n",
      "close to Uganda mainly due to travel and health \n",
      "care transmission mechanisms. Additionally, \n",
      "the non-specific clinical manifestations of EVD \n",
      "including vomiting, diarrhea, sweating, dehy-\n",
      "dration, and hypovolemic shock coupled with \n",
      "undifferentiated symptoms of headache and fa-\n",
      "tigue further complicated the diagnosis due to \n",
      "a simultaneous high burden of other febrile in-\n",
      "fectious diseases. A concurrent wave of malaria \n",
      "cases was reported in Beni which enhanced the \n",
      "difficulty of diagnosis and increased the number \n",
      "of people exposed to Ebola in overcrowded health \n",
      "care facilities with inadequate infection preven-\n",
      "tion and control measures. Eventually, the Min-\n",
      "istry of Health in support of WHO developed a government-led Consolidation and Stabilization \n",
      "Plan for long term Ebola survivor care following \n",
      "the end of the outbreak declaration to strengthen \n",
      "the emergency response capacity and prepared-\n",
      "ness, and overall resilience of the health systems \n",
      "[8, 9]. Despite several warnings and discussions, \n",
      "regular outbreaks of EVD have been noticed in \n",
      "the past decade, making this disease crucial for \n",
      "physicians and infectious diseases specialists to \n",
      "tackle. However, the question arises: when this \n",
      "will stop? Therefore, to answer this question, this \n",
      "narrative review was designed to highlight the \n",
      "clinical aspects associated with EVD, along-with \n",
      "its diagnostic and management approach. \n",
      "n METHODS\n",
      "For this review, a literature search was conduct-\n",
      "ed using PubMed and Google Scholar from in-\n",
      "ception to September 2019. The following search \n",
      "string was used: “Ebola” OR “Ebola virus” OR \n",
      "“Ebola outbreak” OR “Ebola virus pathogenesis” \n",
      "OR “Ebola transmission” OR “Ebola diagnosis” \n",
      "OR “Ebola management.” Articles in languages \n",
      "other than English were excluded. \n",
      "Epidemiology and outbreaks\n",
      "In June 1976, an individual from a rural area in Su-\n",
      "dan, worked in a factory in the township of Nzara \n",
      "presented with complaints of headache, chest pain \n",
      "and fever. The patient developed epistaxis, bleed-\n",
      "ing from the mouth and bloody diarrhea the next \n",
      "day. After infecting several of his colleagues and \n",
      "family members, the patient died on July 6, four \n",
      "days after his admission to the hospital. Accord-\n",
      "ing to the WHO, the characteristics of the disease \n",
      "were found to be similar to those in patients in \n",
      "Marburg, Germany, nine years ago. After lasting \n",
      "for five months from June-November 1976 and \n",
      "infecting 284 people, the epidemic was brought \n",
      "under control, with the mortality being 53% [10].\n",
      "Endemic to Africa, 36 outbreaks have been re-\n",
      "corded in 6 African countries since its detection \n",
      "in 1976. While outbreaks and isolated cases have \n",
      "also been reported in the United States, United \n",
      "Kingdom, Canada, Spain, and Thailand, however, \n",
      "they have been reported as intermittent imported \n",
      "cases [11]. Table 1 and Figure 1 outline Ebola out-\n",
      "breaks from 1976 to 2018 in various parts of the \n",
      "world, constituting of mainly Africa [12]. \n",
      "The largest outbreak to date has been reported 214\n",
      "S. Batra, R.K. Ochani, M.N. Diwan, et al.\n",
      "between the years 2013 and 2016 in West Africa, \n",
      "notably in Guinea, Sierra Leone, and Liberia [13]. \n",
      "Liberia has accounted for roughly 11,000 cases, \n",
      "and over 4,800 deaths out of the unmatched glob-\n",
      "ally reported 28,616 cases and 11,310 casualties \n",
      "[11]. This outbreak included both rural and urban \n",
      "areas with a very high incidence and mortality. \n",
      "Nonetheless, the actual burden might have been \n",
      "markedly greater, owing to under-reporting [13]. \n",
      "Most recent outbreaks were recorded in a remote area in the provinces of Equateur and the North \n",
      "Kivu in the DRC in May and June 2018, respec-\n",
      "tively. According to the reports, most of these out-\n",
      "breaks have been recorded in remote rural areas, \n",
      "but the outbreak in Gulu, Uganda, in 2000 was in \n",
      "a semi-urban area. \n",
      "The Figure 2 outlines the most recent outbreak in \n",
      "Democratic Republic of Congo and Uganda [14].\n",
      "Nevertheless, small outbreaks might not have \n",
      "been identified as such. According to various \n",
      "Table 1 - Outbreaks of Ebola virus from 1976-2020 [12].\n",
      "# Year Country SpeciesCases \n",
      "reportedDeaths \n",
      "Reported\n",
      "1\n",
      "1976Sudan Sudan ebolavirus 284 151 (53%)\n",
      "2 Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 318 280 (88%)\n",
      "3 1979 Sudan Sudan ebolavirus 64 22 (65%)\n",
      "4 1989 Philippines Reston ebolavirus 3 0 (0%)\n",
      "5 1990 United States of America Reston ebolavirus 4 0 (0%)\n",
      "6 1994 Gabon Zaire ebolavirus 51 31 (61%)\n",
      "7 1995 Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 315 254 (81%)\n",
      "8\n",
      "1996South Africa Zaire ebolavirus 2 1 (50%)\n",
      "9 Gabon Zaire ebolavirus 60 45 (95%)\n",
      "10 2000 Uganda Sudan ebolavirus 425 224 (53%)\n",
      "11\n",
      "2001Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 59 44 (75%)\n",
      "12 Gabon Zaire ebolavirus 65 53 (81%)\n",
      "13 2003 Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 143 128 (89%)\n",
      "14 2004 Sudan Sudan ebolavirus 17 7 (41%)\n",
      "15 2005 Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 12 10 (83%)\n",
      "16\n",
      "2007Uganda Bundibugyo ebolavirus 131 42 (32%)\n",
      "17 Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 264 187 (71%)\n",
      "18\n",
      "2008Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 32 15 (47%)\n",
      "19 Philippines Reston ebolavirus 6 0 (0%)\n",
      "20\n",
      "2012Uganda Sudan ebolavirus 6 3 (50%)\n",
      "21 Democratic Republic of the Congo (formerly Zaire) Bundibugyo ebolavirus 38 13 (34%)\n",
      "22 Uganda Sudan ebolavirus 11 4 (36%)\n",
      "23\n",
      "2014Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 69 49 (71%)\n",
      "24 Guinea, Liberia, Sierra Leone (West African Epidemic) Zaire ebolavirus 28610 11,308 (39%)\n",
      "25 Mali Zaire ebolavirus 8 6 (75%)\n",
      "26 Nigeria Zaire ebolavirus 20 8 (40%)\n",
      "27 United States of America Zaire ebolavirus 4 1 (25%)\n",
      "28 2017 Democratic Republic of the Congo (formerly Zaire) Zaire ebolavirus 8 4 (50%)\n",
      "292018-20Democratic Republic of the Congo (formerly Zaire), \n",
      "Uganda Zaire ebolavirus 3310 2264 (68.4%) 215\n",
      "Clinical aspects of Ebola virus disease: a review\n",
      "studies, EVD is mainly endemic to African coun-\n",
      "tries, with some spread to its neighboring coun-\n",
      "tries [13].\n",
      "Pathogenesis\n",
      "EBoV , formerly known as Zaire EBoV , belongs to \n",
      "the Filoviridae family. This species is associated \n",
      "with the greatest number of outbreaks and the \n",
      "highest case-fatality rates among the other four \n",
      "viruses sharing the EBoV genus. The other vi-\n",
      "ruses include Sudan ebolavirus (SUDV), Bundi-\n",
      "bugyo ebolavirus (Bundibugyo virus), Taï Forest ebolavirus (Taï Forest virus), and finally Reston \n",
      "ebolavirus (Reston virus (RESTV) (Figure 3).\n",
      "The EBoV virion is a single-stranded, non-seg-\n",
      "mented, negative-sense RNA that is approximate-\n",
      "ly 19,000 nucleotides long, consisting of 7 genes \n",
      "and 9 proteins [15]. Unlike most of the viral infec-\n",
      "tions, EBOV has high pathogenicity with debili-\n",
      "tating complications, and fatal outcome [16].\n",
      "This pathogenicity is primarily related to its struc-\n",
      "ture, as EBoV is a lipid-enveloped virus that aids \n",
      "the virus into entering the host cell. The viral en-\n",
      "velope glycoprotein (GP) essentially binds to the \n",
      "receptor and binds the viral envelope with the \n",
      "host membrane [17]. Initially, the virus turns off \n",
      "the immune system by affecting the macrophag-\n",
      "es and dendritic cells (antigen-presenting cells), \n",
      "causing their replication. This leads to modula-\n",
      "tion of the genes, which then undergo apoptosis \n",
      "and release viral particles to extracellular tissues \n",
      "[18]. However, later it may affect other several \n",
      "types of cells such as Kupffer cells, hepatocytes, \n",
      "fibroblasts, adrenal gland cells leading to the \n",
      "spread of disease, and causing vascular damage \n",
      "and multi-organ failure [19].\n",
      "The virus disrupts the immune system by sup-\n",
      "pressing the maturation of dendritic cells, which \n",
      "leads to disruption in the production of inflam-\n",
      "Figure 1 - Global distribution of EBoV from 1976-2018.\n",
      "Figure 2 - EBoV from 2018-2020.216\n",
      "S. Batra, R.K. Ochani, M.N. Diwan, et al.\n",
      "matory cytokines that impairs their ability to acti-\n",
      "vate T-cells [2, 19, 20]. In vitro studies indicate that \n",
      "VP35 is involved in blocking the host interferons \n",
      "production and signaling by suppressing the ac-\n",
      "tivation of T-cells and expression of cytokines \n",
      "when activated by a RIGI-like receptor signaling. \n",
      "While, VP24 directly inhibits Interferon a/b and \n",
      "Interferon g (IFN) signaling by inhibiting the di-\n",
      "merization of phosphorylated STAT1, ultimately \n",
      "blocking the transcription of anti-viral genes [15, \n",
      "21]. Additionally, IFNs also upregulate expression \n",
      "of major histocompatibility complex on host cell \n",
      "surfaces’ which generally plays an essential role \n",
      "in innate immune response [2].\n",
      "Furthermore, the virus further suppresses the im-\n",
      "munity by causing apoptosis of bystander lympho-\n",
      "cytes, most probably via FasL/FasR receptor bind-\n",
      "ing (extrinsic pathway), and possibly via upregulat-\n",
      "ing TNF-α  production inducing viral damage to the \n",
      "surrounding tissue (intrinsic pathway) [2, 22, 23]. In \n",
      "addition to weakening the immune system, the re-\n",
      "lease of vast amounts of cytokines and chemokines, \n",
      "results in increased activation of coagulation cas-\n",
      "cade causing damage to the vascular integrity and \n",
      "permeability. This damage in the vessels may lead \n",
      "to hypovolemic shock, and subsequently, dissemi-\n",
      "nated intravascular coagulation plays a huge role in \n",
      "the mortalities associated with EHF [19, 20, 23]. \n",
      "Vectors, transmission and reservoirs\n",
      "Members of the Pteropodidae family, Fruit bats, are \n",
      "considered as the most likely natural reservoir of EBoV [24]. With an incubation period of 4 to 10 \n",
      "days, EBoV has a biosafety level 4 and category \n",
      "A bioterrorism pathogen with a significant trans-\n",
      "mission probability throughout the nation [11]. \n",
      "Liquid or dried material both can help the virus \n",
      "survive for many days [25]. \n",
      "Blood, feces, and vomit are considered as most \n",
      "infectious bodily fluids, according to WHO [26]. \n",
      "Such fluids are considered as highly transmitta-\n",
      "ble by direct contact from dead or living infected \n",
      "persons. Non-animal objects contaminated with \n",
      "infected bodily fluids (fomites) may also transmit \n",
      "the disease [25]. However, the relative infectivity \n",
      "of the various body fluids of patients with EVD \n",
      "has not been established yet. Although well docu-\n",
      "mented, the risk associated with sexual transmis-\n",
      "sion remains low [24]. \n",
      "So far, direct contact with a symptomatic or dead \n",
      "EVD case is the major route of transmission [25]. \n",
      "Humans can also get infected with EBoV via \n",
      "contact with wild animals in situations such as \n",
      "hunting and preparing meat from infected ani-\n",
      "mals [26]. \n",
      "Along with no documentation of airborne trans-\n",
      "mission, attempts to culture virus from the amni-\n",
      "otic fluid have not been reported either. Further -\n",
      "more, high levels of viral RNA in amniotic fluid \n",
      "of pregnant women infected with EVD and on the \n",
      "placenta and fetus right after delivery. These fac-\n",
      "tors, along with elevated in utero fetal and neona-\n",
      "tal fatality rates, are strong indicators of vertical \n",
      "transmission of EVD [24, 25].\n",
      "Figure 3 - Taxonomy of Ebola Virus.217\n",
      "Clinical aspects of Ebola virus disease: a review\n",
      "Clinical manifestations \n",
      "With an incubation period ranging from 2 to 21 \n",
      "days - high fever, fatigue, malaise, body aches, \n",
      "and chills represent EVD as a flu-like syndrome. \n",
      "The disease also commonly manifests as gastro-\n",
      "intestinal (abdominal pain and anorexia), respira-\n",
      "tory (chest pain and dyspnea), vascular (postural \n",
      "hypotension and edema), and rarely neurologic \n",
      "(headache, delirium, confusion and coma) disor -\n",
      "ders [2, 13]. Furthermore, low serum concentra-\n",
      "tions of potassium, sodium and calcium have also \n",
      "been commonly reported in EVD patients, prov-\n",
      "ing them to be important causes of death along \n",
      "with dehydration [27]. Although discretely visible \n",
      "on patients with dark skin, a maculopapular rash \n",
      "has also been reported as one of the findings [13].\n",
      "If pregnant, such women have a high probability \n",
      "of transmitting the disease to their infants either \n",
      "by breast milk or by close contact. Such women \n",
      "also have an increased risk of miscarriage, and as \n",
      "suggested by clinical findings, high children of in-\n",
      "fected mothers have a high mortality rate [2].\n",
      "Death typically occurs between days 6 and 16, \n",
      "even though the patients with the fatal disease \n",
      "develop clinical manifestation during early in-\n",
      "fection. The causes of death include hypovolemic \n",
      "shock and multiorgan failure [2]. Although in cer -\n",
      "tain cases, sudden death can occur due to cardi-\n",
      "ac arrhythmias. Nevertheless, if patients survive \n",
      "the stage of shock, there is a possibility of gradu-\n",
      "al recovery. Even though several studies tried to \n",
      "identify clinical manifestations for EVD, their di-\n",
      "agnostic accuracy was too little to rely upon, ren-\n",
      "dering them inaccurate to be included in clinical \n",
      "triage systems [13].\n",
      "Diagnosis\n",
      "The EVD presents with clinical manifestations de-\n",
      "picting a flu-like syndrome, and many differential \n",
      "diagnoses must be considered to eliminate the \n",
      "possibility of diseases including malaria, typhoid \n",
      "fever and meningococcal meningitis. Hence, it \n",
      "is imperative for clinicians to consider the travel \n",
      "and exposure history when treating a suspected \n",
      "patient returning from an endemic area of EVD [2, \n",
      "7]. In accordance with a study conducted by Col-\n",
      "lier et al., abnormal laboratory findings in an EVD \n",
      "involves leukopenia (as low as 1000 cells/L) with \n",
      "a left shift, thrombocytopenia (50,000-100,000 \n",
      "cells/L) prolonged bleeding time and prothrom-\n",
      "bin time, hyperproteinemia and hematuria [28]. Moreover, the EHF presents with early non-spe-\n",
      "cific symptoms and a high index of suspicion is \n",
      "needed in diagnosis. However, identification of \n",
      "the EBoV is not required for the initial diagnosis \n",
      "of EHF. It is usually diagnosed based on multi-\n",
      "ple virologic consequences such as sudden onset \n",
      "of illness, high fevers (>101°F) for less than three \n",
      "weeks, at least two hemorrhagic symptoms (e.g., \n",
      "epistaxis, bloody stools, or hemoptysis) despite \n",
      "no predisposing factors for hemorrhagic manifes-\n",
      "tations generally provides ample evidence to the \n",
      "clinicians to consider EHF and begin supportive \n",
      "treatment until confirmation of the virus is pro-\n",
      "vided by the laboratory findings [29].\n",
      "The specific diagnosis of EHF and EVD requires \n",
      "laboratory evidence that should be performed in \n",
      "a well-equipped laboratory with biosafety level \n",
      "4 bio-contaminant facilities keeping in view the \n",
      "high biohazardrisk associated with testing [30]. \n",
      "Serologic testing for the Ebola viral antibodies \n",
      "includes enzyme-linked immunosorbent assay \n",
      "(ELISA), radioimmunoassay (RIA), radioimmu-\n",
      "noprecipitation assay (RIPA), and Western blot \n",
      "analysis which is an immunoassay of viral pro-\n",
      "teins separated by polyacrylamide gel electropho-\n",
      "resis and transferred to a paper medium [31]. RIA \n",
      "is a sensitive radioimmunoassay that uses 125I-Ia-\n",
      "beled staphylococcal protein A and was utilized \n",
      "by Douglas and Cleveland to distinguish between \n",
      "the two strains of the Ebola virus from the 1976 \n",
      "outbreaks of acute hemorrhagic fever in southern \n",
      "Sudan (SUDV) and northern Zaire (EOBV) [32]. \n",
      "The RIPA and the Western blot analysis measure \n",
      "antibody responses to individual viral proteins, \n",
      "thus showing molecular specificity to response \n",
      "and are used as secondary confirmatory serologic \n",
      "tools. The most sensitive serologic tool to detect \n",
      "antibodies to EBoV is the ELISA used for both pri-\n",
      "mates and humans. It is favorable in epidemiolog-\n",
      "ical studies and on-going surveillance programs. \n",
      "Immunoglobulin (Ig) M antibodies to Ebola virus \n",
      "appear as early as six days after symptoms begin \n",
      "and disappear in less than 90 days while IgG an-\n",
      "tibodies appear more slowly after symptom on-\n",
      "set but persist for many months (>400 days) [31]. \n",
      "IgM and IgG antibodies do not develop in all \n",
      "fatal cases and can only be used in a fraction of \n",
      "symptomatic patients, requiring seroconversion \n",
      "or a substantial increase in antibody titer for un-\n",
      "ambiguous diagnosis. However, it is the method \n",
      "utilized by clinicians to diagnose asymptomatic 218\n",
      "S. Batra, R.K. Ochani, M.N. Diwan, et al.\n",
      "Ebola virus infections, which are characterized by \n",
      "extremely low viremia and development of IgG \n",
      "and IgM about three weeks after infection [33].\n",
      "Real-time reverse transcription-polymerase chain \n",
      "(RT-PCR) reaction for clinical blood and oral swab \n",
      "specimens, as well as immunohistochemistry on a \n",
      "skin biopsy, are most used to diagnose post-mortem \n",
      "EVD in people who died before hospitalization \n",
      "[34, 35]. RT-PCR was used for the rapid diagno-\n",
      "sis of EHF during the largest outbreak in Uganda \n",
      "(2000-2001). After the initial diagnosis of SUDV , \n",
      "viral antigen detection by ELISA and RT-PCR was \n",
      "used to diagnose SUDV infection in suspected \n",
      "patients and proved very useful for detecting the \n",
      "virus in patient serum, plasma, and whole blood. \n",
      "The RT-PCR assay could also detect the Ebola vi-\n",
      "rus 24-48 hours prior to detection by antigen cap-\n",
      "ture in a sample collected during the early phase \n",
      "of infection [36]. RT-PCR was originally devel-\n",
      "oped and implemented during the EHF outbreaks \n",
      "in Gabon in 1996. Due to the high mortality and \n",
      "transmissibility rates, immediate diagnoses using \n",
      "relatively sophisticated techniques were essential \n",
      "for surveillance and control. Since the peripheral \n",
      "blood mononuclear cell (PBMC) is known to be \n",
      "targets for filovirus; this technique was utilized \n",
      "to detect the Ebola virus in these cells. RT-PCR \n",
      "results were also compared with ELISA antigen \n",
      "capture, and Ebola specific IgM and IgG antibody \n",
      "detection [37].\n",
      "RT-PCR proved to be more sensitive in identi-\n",
      "fying acute infection and early convalescence \n",
      "as compared to antigen and IgM detection with \n",
      "a sensitivity of 100% and 91%, respectively. The \n",
      "specificity compared with antigen detection and \n",
      "IgM assay combined was 97%. Antigen capture \n",
      "was able to detect only 83% of those viruses iden-\n",
      "tified by PCR, while only 67% of the viruses were \n",
      "identified by IgM [36]. A novel technique of im-\n",
      "munohistochemistry (IHC) testing using forma-\n",
      "lin-fixed postmortem skin specimens (skin biop-\n",
      "sy) was used as a diagnostic procedure for the \n",
      "EHF outbreak in the DRC (1995). In the IHC test-\n",
      "ing, EBoV antigens were seen primarily within \n",
      "endothelial cells, mononuclear phagocytic cells, \n",
      "and hepatic sinusoids, indicating these cells to be \n",
      "the primary target of Filovirus. IHC also showed \n",
      "an association of cellular damage with the viral \n",
      "infection and abundant viral antigens in the skin \n",
      "of EHF patients showed transmission by contact \n",
      "to be responsible for epidemics [38].Management and treatment \n",
      "Management of patients suffering from EVD in-\n",
      "volves supportive care such as maintaining fluid \n",
      "along with electrolyte balance, blood pressure \n",
      "and oxygen saturation. This also includes treating \n",
      "complications arising from secondary infections. \n",
      "However, multiple medical, immunotherapy and \n",
      "nucleic acid therapy approaches have been re-\n",
      "ported and are under further investigation. \n",
      "Prophylactic strategies for EVD \n",
      "In the absence of pre-exposure prophylaxis to \n",
      "prevent the disease through non-pharmacologic \n",
      "means by creating a barrier to transmission, an-\n",
      "ti-viral agents could be used for post-exposure \n",
      "prophylaxis or treatment to reduce the disease \n",
      "severity, virus transmission, and duration of clin-\n",
      "ical manifestations. These therapeutic agents are \n",
      "available in different formulations and can be \n",
      "administered via the oral, intramuscular, or in-\n",
      "travenous routes. Measurement of end-organ and \n",
      "immune system function, in addition to the fre-\n",
      "quency and duration of prophylaxis, must all be \n",
      "considered for an effective post-exposure prophy-\n",
      "lactic agent [39, 40].\n",
      "Anti-viral therapy for EVD\n",
      "Due to the requirement of biosafety level 4 facil-\n",
      "ities in a laboratory, researches have employed \n",
      "reverse genetics to identify new targets within \n",
      "viral genomes of the EBoV for drug and vaccine \n",
      "development. Reverse genetics allows the devel-\n",
      "opment of recombinant filoviruses, such as EBoV , \n",
      "containing key gene sequences but are non-rep-\n",
      "licating and hence non-infective. This technique \n",
      "has been used by Martinez and colleagues to un-\n",
      "derstand gene function in EBoV research to study \n",
      "virus entry, replication and assembly [41]. Ribavi-\n",
      "rin and lamivudine have been tried as a means to \n",
      "treat EVD. Ribavirin interferes with the capping \n",
      "of the viral mRNA, while lamivudine is a nucle-\n",
      "oside analogue that interferes in gene replication. \n",
      "However, ribavirin resulted in reduced mortality \n",
      "in human cases of Lassa fever and monkeys with \n",
      "Rift Valley fever virus but has not been effective \n",
      "in animal models of filoviral and flaviviral in-\n",
      "fections [42]. Furthermore, no apparent survival \n",
      "benefit was observed with lamivudine treatment \n",
      "[43]. Another anti-viral agent known as T-705 (fa-\n",
      "vipiravir) has undergone animal trials to evaluate \n",
      "its efficacy against EBoV . Although it was initially 219\n",
      "Clinical aspects of Ebola virus disease: a review\n",
      "developed by Fujifilm, Japan for treating influen-\n",
      "za virus infection by inhibiting a viral enzyme, \n",
      "the animal studies have now confirmed that fa-\n",
      "vipiravir is effective in treating animals infected \n",
      "with the aerosolized E718 strain of EBoV [44, 45].\n",
      "Immunotherapies\n",
      "Passive immune therapy or convalescent im-\n",
      "mune plasma for treatment of EVD was original-\n",
      "ly used in a 1995 outbreak in Kikwit, Zaire. Mu-\n",
      "papa and his colleagues utilized this therapy to \n",
      "treat eight patients with EVD, out of which seven \n",
      "survived [46]. This technique uses plasma from \n",
      "recovered EVD patients to neutralize antibodies. \n",
      "WHO issued recent guidelines for the potential \n",
      "use of blood products from EVD survivors. This \n",
      "guideline addressed various issues ranging from \n",
      "identification of suitable blood or plasma donors \n",
      "among EVD survivors, donor consent and selec-\n",
      "tion, donor blood collection, as well as storage of \n",
      "whole blood and plasma along with transporta-\n",
      "tion [47].\n",
      "Zmapp\n",
      "This experimental drug was used for some pa-\n",
      "tients during the 2014 West Africa Ebola out-\n",
      "break, and several people survived. It compris-\n",
      "es of a combination of three humanized murine \n",
      "antibodies generated by EBoV infected mice and \n",
      "produced in tobacco plants. This combination of \n",
      "antibodies binds to and inactivates the virus. In \n",
      "animal studies, 43% of infected mice survived \n",
      "with Zmapp treatment. However, no randomized \n",
      "controlled clinical trials exist to investigate wheth-\n",
      "er Zmapp is effective for patients suffering from \n",
      "EVD [43, 44 ,48].\n",
      "Vaccination and prevention\n",
      "Despite the discovery of the EBoV in 1976, it was \n",
      "not until 2014 the world saw the virus’s destruc-\n",
      "tive potential. The epidemic outbreak of Ebola in \n",
      "West Africa leading to unprecedented numbers of \n",
      "cases and deaths, heralded the scientific commu-\n",
      "nities throughout the world to work on the de-\n",
      "velopment of the Ebola vaccine, ideal for use in \n",
      "an outbreak setting. WHO and a number of other \n",
      "public health experts, trial centers, funders, glob-\n",
      "al stakeholders and agencies collaborated for this \n",
      "cause. Various clinical trials were rapidly initiated \n",
      "in Africa and Australia, while the United States, \n",
      "Europe, and Asia started designing and manufac-turing new vaccines. Regulatory and ethical re-\n",
      "views of clinical trial protocols were immediately \n",
      "done in Europe, North America, and Africa [49].\n",
      "Anti-Ebola Virus vaccine efforts have been in pro-\n",
      "gress for the past 2 decades, culminating in over \n",
      "12 different vaccine candidates that have been \n",
      "placed into several clinical trials [50]. However, \n",
      "it was not until December 19th, 2019 when finally \n",
      "the U.S. Food and Drug Administration approved \n",
      "the Ebola vaccine rVSV-ZEBOV . The rVSV-ZE-\n",
      "BOV vaccine is a single dose injection, and is a \n",
      "live, attenuated vaccine that has been genetically \n",
      "engineered to contain a protein from the Zaire eb-\n",
      "olavirus. \n",
      "The approval of rVSV-ZEBOV is supported by \n",
      "a study conducted in Guinea during the 2014-\n",
      "2016 outbreak in individuals 18 years of age and \n",
      "older. This study was an open-label, cluster-ran-\n",
      "domized phase III trial using an innovative ring \n",
      "vaccination protocol [51, 52]. The phase III clinical \n",
      "trial study reported promising results providing \n",
      "significant protection against EBOV-mediated \n",
      "disease and no new cases reported in either ran-\n",
      "domized or non-randomized clusters of contacts \n",
      "around confirmed EBOV virus disease patients. \n",
      "Disease control\n",
      "The key to managing EBoV epidemics is to stop \n",
      "the transmission and interrupt the spread of dis-\n",
      "ease in the most affected population. This is pos-\n",
      "sible through early case identification/interven-\n",
      "tion, rapid isolation, clinical management, public \n",
      "awareness and support, and transversal coordina-\n",
      "tion. Insufficient resources and lack of awareness \n",
      "played a major role in the 2014 Ebola outbreak. It \n",
      "was an alarming situation highlighting the weak-\n",
      "ened and understaffed health care system. Hence, \n",
      "in August 2014, a partnership between WHO, \n",
      "Ministries of Health, Centers for Disease Control \n",
      "and Prevention (CDC) and others was established \n",
      "to uplift the infection prevention and control \n",
      "practices in health care facilities [13, 53].\n",
      "Rapid identification requires aggressive surveil-\n",
      "lance systems for the anticipation of outbreaks \n",
      "in areas at risk. Advanced technology and relia-\n",
      "ble laboratory testing techniques are vital for the \n",
      "immediate detection of the EBoV and other hem-\n",
      "orrhagic fever viruses. The advantages of nov-\n",
      "el diagnostic technologies and rapid laboratory \n",
      "response are highlighted in managing the EBoV \n",
      "outbreak in the DRC in 2018 [54].220\n",
      "S. Batra, R.K. Ochani, M.N. Diwan, et al.\n",
      "Isolation of the suspected case and monitoring of \n",
      "the contacts is the next major step to interrupt the \n",
      "chains of transmission. Establishment of Ebola \n",
      "treatment centers (ETCs) where quality care and \n",
      "well-equipped staff are provided for the patients, \n",
      "is crucial in order to achieve this. These treatment \n",
      "centers should be located close to the affected \n",
      "communities and should be designed in a way \n",
      "that families can get involved in the care of their \n",
      "close ones and visit their affected family mem-\n",
      "bers. Efficient transportation facilities should also \n",
      "be available to move the patient quickly [55-57].\n",
      "Setting up these ETCs in time, especially in re-\n",
      "mote areas where the virus usually emerges, re-\n",
      "quires the importation of equipment, supplies, \n",
      "and experts in medical professionals along with \n",
      "logistical support for proper planning of the in-\n",
      "frastructure. For this to happen, we need global \n",
      "organizations that provide rapid comprehensive \n",
      "epidemic support and the resources that are re-\n",
      "quired for clinical management [58]. Medical pro-\n",
      "fessionals and the healthcare workers involved in \n",
      "patient transport and cleanup of infectious mate-\n",
      "rial should be vaccinated. Moreover, they should \n",
      "use personal care equipment to safeguard them-\n",
      "selves and avoid contact with blood and body flu-\n",
      "ids of Ebola patients [59].\n",
      "Public awareness, in order to gain the public sup-\n",
      "port, is essential to limit the spread of the disease. \n",
      "Various strategies like contact tracing, burial prac-\n",
      "tices, quarantine/restriction of the movements \n",
      "have the potential to curtail an outbreak. Howev-\n",
      "er, resistance from the community is a significant \n",
      "hindrance to the implementation of these strate-\n",
      "gies, primarily because of the people’s perception \n",
      "regarding their social and cultural values being \n",
      "violated. Contact tracing includes identification, \n",
      "listing, and monitoring of the contacts of patients \n",
      "with the EBoV . A survey in Liberia during 2014-\n",
      "2015 highlighted the success of this strategy as \n",
      "it helped in detecting 3-6% of new cases [60]. Al-\n",
      "though scarcity of resources like ambulances and \n",
      "skilled human force might restrict the practice \n",
      "of contact tracing, effective community involve-\n",
      "ment and reciprocity will allow contact tracing \n",
      "even when the resources are limited. Addition-\n",
      "ally, enforcement of safe burial practices is a ma-\n",
      "jor contribution to control of the EBoV outbreak. \n",
      "However, practices such as the use of plastic bags \n",
      "without burial clothes and prayers face a massive \n",
      "backlash from the community as they are against their honor and traditions. Therefore, improving \n",
      "these procedures by making them more flexible \n",
      "in accordance with the community traditions and \n",
      "ensuring all the essential safety precautions can \n",
      "significantly increase the compliance of safe bur -\n",
      "ial activities. Also, female members should be a \n",
      "part of the burial team to bury female bodies [57].\n",
      "Implementation of all the interventions men-\n",
      "tioned above will not be possible without interna-\n",
      "tional aid and funds, a high level of coordination \n",
      "and acceptance from the community. Nonethe-\n",
      "less, if all the mentioned approaches are success-\n",
      "fully implemented, there is a pronounced likeli-\n",
      "hood of controlling the spread of the disease.\n",
      "n CONCLUSION\n",
      "Frequent outbreaks of EBoV have caused numer -\n",
      "ous mortalities and morbidities. Since the virus \n",
      "may lead to a pandemic, its prevention has be-\n",
      "come of utmost importance as it is highly capable \n",
      "of causing significant physical and economic bur -\n",
      "den. Hence, there is a dire need to conduct clini-\n",
      "cal trials on EBoV to establish possible treatment \n",
      "regimens to prevent any further outbreaks.\n",
      "Funding\n",
      "None\n",
      "Conflict of interest\n",
      "None to declare\n",
      "n REFERENCES\n",
      "[1] Report of an International Commission. Ebola \n",
      "haemorrhagic fever in Zaire, 1976. Bull World Health Or-\n",
      "gan. 1978; 56 (2), 271-93.\n",
      "[2] H. Feldmann, T.W. Geisbert. Ebola haemorrhagic fe-\n",
      "ver. Lancet. 2012; 377 (9768), 849-62.\n",
      "[3] J.H. Kuhn, S. Becker, H. Ebihara, et al. Proposal for \n",
      "a revised taxonomy of the family Filoviridae: classifi-\n",
      "cation, names of taxa and viruses, and virus abbrevia-\n",
      "tions. Arch Virol. 2010; 155 (12), 2083-2103.\n",
      "[4] Leroy EM, Kumulungui B, Pourrut X, et al. Fruit \n",
      "bats as reservoirs of Ebola virus. Nature. 2005; 438 \n",
      "(7068), 575-6.\n",
      "[5] Groseth, H. Feldmann, J.E. Strong. The ecology of \n",
      "Ebola virus. Trends Microbiol. 2007; 15 (9), 408-16.\n",
      "[6] Centers for Disease Control and Prevention. 2014-2016 \n",
      "Ebola Outbreak in West Africa. Retrieved from https://\n",
      "www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/\n",
      "index.html. Last accessed March 16, 2020.\n",
      "[7] Sanchez TW, Feldmann GH. Filoviridae. Marburg 221\n",
      "Clinical aspects of Ebola virus disease: a review\n",
      "and Ebola viruses, In D.M. Knipe, P .M. Howley (Eds.), \n",
      "Fields virology. Lippincott Williams & Wilkins, Philadel-\n",
      "phia; 1985; 1409-48\n",
      "[8] Kalenga OI, Moeti M, Sparrow A et al. The Ongoing \n",
      "Ebola Epidemic in the Democratic Republic of Congo, \n",
      "2018-2019. N Engl J Med. 2019; 381, 373-83.\n",
      "[9] World Health Organization. Ebola virus disease – \n",
      "Democratic Republic of the Congo. Disease outbreak \n",
      "news 25 July 2018. Retrieved from https://www.who.\n",
      "int/csr/don/25-july-2018-ebola-drc/en/ Last accessed \n",
      "March 16, 2020.\n",
      "[10] Murray MJ. Ebola Virus Disease: A Review of Its \n",
      "Past and Present. Anesth Analg. 2015; 121(3), 798-809.\n",
      "[11] Hasan S, Ahmad SA, Masood R, et al. Ebola virus: \n",
      "A global public health menace: A narrative review. J \n",
      "Family Med Prim Care. 2019; 8 (7), 2189-2201.\n",
      "[12] Centers for Disease Control and Prevention. 40 \n",
      "Years of Ebola Virus Disease around the World. 2019. \n",
      "Retrieved from https://www.cdc.gov/vhf/ebola/his-\n",
      "tory/chronology.html. Last accessed December 25, 2019.\n",
      "[13] Malvy D, McElroy AK, de Clerck H. Lancet. 2019; \n",
      "393 (10174), 936-48.\n",
      "[14] Medecins Sans Frontieres. DRC Ebola outbreaks, \n",
      "Crisis update – March 2020. Retrieved from: https://\n",
      "www.msf.org/drc-ebola-outbreak-crisis-update. Last \n",
      "accessed March 10, 2020\n",
      "[15] Kiley MP , Bowen ET, Eddy GA, et al. Filoviridae: a \n",
      "taxonomic home for Marburg and Ebola viruses? Inter-\n",
      "virology. 1982; 18, 24-32. \n",
      "[16] Zhang L, Wang H. Forty years of the war against \n",
      "Ebola. J Zhejiang Univ Sci B. 2014; 15 (9), 761-5.\n",
      "[17] Yang Z, Duckers HJ, Sullivan NJ, et al. Identifica-\n",
      "tion of the Ebola virus glycoprotein as the main viral \n",
      "determinant of vascular cell cytotoxicity and injury. Nat \n",
      "Med. 2000; 6 (8), 886-9.\n",
      "[18] Fowler RA, Fletcher T, Fischer WA 2nd, et al. Car -\n",
      "ing for critically ill patients with ebola virus disease. \n",
      "Perspectives from West Africa.Am J Respir Crit Care \n",
      "Med. 2014; 190 (7), 733-7.\n",
      "[19] Furuyama W, MarziA.Ebola Virus: Pathogenesis \n",
      "and Countermeasure Development. Annu Rev Virol. \n",
      "2019; 6 (1), 435-58. \n",
      "[20] Bociaga-Jasik M, Piatek A, GarlickiA.Ebola virus \n",
      "disease - pathogenesis, clinical presentation and man-\n",
      "agement. Folia Med Cracov. 2014; 54 (3), 49-55.\n",
      "[21] Yen B, Mulder LCF, Martinez O, et al. Molecular \n",
      "basis for Ebolavirus VP35 suppression of human den-\n",
      "dritic cell maturation. J Virol. 2014; 88 (21), 12500-10. \n",
      "[22] Bradfute SB, Swanson PE, Smith MA, et al. Mech-\n",
      "anisms and consequences of ebolavirus-induced lym-\n",
      "phocyte apoptosis. J Immunol. 2010; 184 (1), 327-35. \n",
      "[23] Wauquier N, Becquart P , Padilla C, et al. Human \n",
      "fatal Zaire ebola virus infection is associated with an \n",
      "aberrant innate immunity and with massive lympho-\n",
      "cyte apoptosis. PLoSNegl Trop Dis. 2010; 4 (10), e837. \n",
      "[24] Vetter P , Fischer WA, Schibler M, et al. Ebola Virus Shedding and Transmission: Review of Current Evi-\n",
      "dence. J Infect Dis. 2016; 214 (Suppl. 3), S177-S184.\n",
      "[25] Rewar S, Mirdha D. Transmission of Ebola virus dis-\n",
      "ease: an overview. Ann Glob Health 2014; 80 (6), 444-51.\n",
      "[26] Gebretadik FA, Seifu MF, Gelaw BK. Review on \n",
      "Ebola Virus Disease: Its outbreak and current status. \n",
      "Epidemiology. 5, 204.\n",
      "[27] Roberts I, Perner A. Ebola virus disease: clinical \n",
      "care and patient-centred research. Lancet. 2014; 384, \n",
      "2001-2. \n",
      "[28] Collier L, Balows A, Sussman M. Topley and Wil-\n",
      "son’s microbiology and microbial infections, 9th ed. Oxford \n",
      "University Press, New York; 1998.\n",
      "[29] Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic \n",
      "fever viruses as biologicalweapons—medical and pub-\n",
      "lic health management. JAMA. 2002; 287 (18), 2391-405.\n",
      "[30] Ebola Virus Infection. Taiwan Centers for Disease \n",
      "Control. Available at: https://www.cdc.gov.tw/. Last \n",
      "accessed January 5, 2020.\n",
      "[31] Ksiazek TG, West CP , Rollin PE. ELISA for the de-\n",
      "tection of antibodies to Ebola viruses. J Infect Dis. 1999; \n",
      "179 (Suppl. 1), S192-8.\n",
      "[32] Richman DD, Cleveland PH, McCormick JB, et al. \n",
      "Antigenic Analysis of Strains of Ebola Virus: Identifi-\n",
      "cation of Two Ebola Virus Serotypes. J Infect Dis. 1983; \n",
      "147 (2), 268-71. \n",
      "[33] Leroy EM, Baize S, Volchkov VE, et al. Human \n",
      "asymptomatic Ebola infection and strong inflammatory \n",
      "response. Lancet. 2000; 355, 2210-2215.\n",
      "[34] Erickson BR, Sealy TK, Flietstra T, et al. Ebola virus \n",
      "disease diagnostics, Sierra Leone: analysis of real-time \n",
      "reverse transcription-polymerase chain reaction values \n",
      "for clinical blood and oral swab specimens. J Infect Dis. \n",
      "2016; 214, S258-S262.\n",
      "[35] Zaki SR, Shieh WJ, Greer P , et al. A novel immu-\n",
      "nohistochemical assay for the detection of Ebola virus \n",
      "in skin: implications for diagnosis, spread, and surveil-\n",
      "lance of Ebola hemorrhagic fever. Commission de Lut-\n",
      "tecontre les Epidemies a Kikwit. J Infect Dis. 1999; 179, \n",
      "S36-S47.\n",
      "[36] Towner JS, Rollin PE, Bausch DG, et al. Rapid diag-\n",
      "nosis of Ebola hemorrhagic fever by reverse transcrip-\n",
      "tion-pcr in an outbreak setting and assessment of pa-\n",
      "tient viral load as a predictor of outcome. J Virol. 2004; \n",
      "78 (8), 4330-41.\n",
      "[37] Leroy E, Baize S, Lu C, et al. Diagnosis of Ebola \n",
      "haemorrhagic fever by RT-PCR in an epidemic setting. \n",
      "J Med Virol. 2000; 60, 463-7. \n",
      "[38] Sherif RZ, Wun-JuShieh, Patricia W, et al. A novel \n",
      "immunohistochemical assay for the detection of Ebola \n",
      "virus in skin: implications for diagnosis, spread, and \n",
      "surveillance of Ebola hemorrhagic fever. J Infect Dis. \n",
      "1999; 179(1), S36-S47.\n",
      "[39] Mupapa K, Mukundu W, Bwaka MA, et al. Ebola \n",
      "hemorrhagic fever and pregnancy. J Infect Dis. 1999a; \n",
      "179(Suppl. 1), S11-2.222\n",
      "S. Batra, R.K. Ochani, M.N. Diwan, et al.\n",
      "[40] Jamieson DJ, Uyeki TM, Callaghan WM, et al. \n",
      "What obstetrician-gynecologists should know about \n",
      "ebola: a perspective from the centers for disease control \n",
      "and prevention? Obstet Gynecol. 2014; 124 (5), 1005-10.\n",
      "[41] Martinez MJ, Volchkova VA, Raoul H, et al. Role \n",
      "of VP30 phosphorylation in the Ebola virus replication \n",
      "cycle. J Infect Dis. 2011; 204 (Suppl. 3), S934-40.\n",
      "[42] Huggins JW. Prospects for treatment of viral hem-\n",
      "orrhagic fevers with ribavirin, a broad-spectrum antivi-\n",
      "ral drug. Rev Infect Dis. 1989; 11 (Suppl. 4), S750-S761.\n",
      "[43] Centers for Disease Control and Prevention. Eb-\n",
      "ola virus disease Information for Clinicians in U.S. \n",
      "Healthcare Settings. CDC USA Website. Retrieved from \n",
      "http://www.cdc.gov/vhf/ebola/hcp/clinician-in-\n",
      "formation-us-healthcare-settings.html#investigation-\n",
      "al-vaccines. Last accessed January 4, 2020.\n",
      "[44] Butler D. Ebola drug trials set to begin amid crisis. \n",
      "Nature. 2014; 513, 13-14.\n",
      "[45] Smither SJ, Eastaugh LS, Steward JA, et al. Post-ex-\n",
      "posure efficacy of oral T-705 (Favipiravir) against inha-\n",
      "lational Ebola virus infection in a mouse model. Antivi-\n",
      "ral Res. 2014; 104, 153-5.\n",
      "[46] Mupapa K, Massamba M, Kibadi K, et al. Treat-\n",
      "ment of Ebola hemorrhagic fever with blood transfu-\n",
      "sions from convalescent patients. International Scien-\n",
      "tific and Technical Committee. J Infect Dis. 1999; 179 \n",
      "(Suppl. 1), S18-23.\n",
      "[47] World Health Organization. Use of Convalescent \n",
      "Whole Blood or Plasma Collected from Patients Re-\n",
      "covered from Ebola Virus Disease for Transfusion as \n",
      "an Empirical Treatment during Outbreaks. Version 1.0. \n",
      "2014. Retrieved from https://apps.who.int/iris/han-\n",
      "dle/10665/135591. Last accessed December 6, 2019.\n",
      "[48] Pettitt J, Zeitlin L, Kim DH, et al. Therapeutic in-\n",
      "tervention of Ebola virus infection in rhesus macaques \n",
      "with the MB-003 monoclonal antibody cocktail. Sci \n",
      "Transl Med. 2013; 5, 199, 199ra-113.\n",
      "[49] Venkatraman N. Vaccines against Ebola Virus. Vac -\n",
      "cine. 2017; 36 (36), 5454-59.\n",
      "[50] Centers for Disease Control and Prevention. Eb-\n",
      "ola (Ebola Virus Disease), Prevention and Vaccine. \n",
      "Retrieved from: https://www.cdc.gov/vhf/ebola/\n",
      "prevention/index.html?fbclid=IwAR01HUk6eO-J7apF3eqA7j_C6MwF5OeWWfnIbMHN9R8yQX1b -\n",
      "0jvQ8wWRgihU. Last accessed March 15, 2020\n",
      "[51] Henao-Restrepo AM, Camacho A, Longini IM, et al. \n",
      "Efficacy and effectiveness of an rVSV-vectored vaccine \n",
      "in preventing Ebola virus disease: final results from the \n",
      "Guinea ring vaccination, open-label, cluster-randomised \n",
      "trial (Ebola ÇaSuffit!). Lancet. 2017; 389 (10068), 505-18.\n",
      "[52] Henao-Restrepo AM, Longini IM, Egger M, et al. \n",
      "Efficacy and effectiveness of an rVSV-vectored vaccine \n",
      "expressing Ebola surface glycoprotein: interim results \n",
      "from the Guinea ring vaccination cluster-randomised \n",
      "trial. Lancet. 2015; 386 (9996), 857-66.\n",
      "[53] Hageman JC. Infection prevention and control for \n",
      "Ebola in health care settings - West Africa and United \n",
      "States. MMWR supple 2016; 65 (3), 50-6.\n",
      "[54] Mbala-Kingebeni P , Villabona-Arenas CJ, Vidal N, \n",
      "et al. Rapid confirmation of the Zaire Ebola virus in the \n",
      "outbreak of the Equateur province in the Democratic \n",
      "Republic of Congo: implications for public health inter -\n",
      "ventions. Clin Infect Dis. 2018; 68 (2), 330-3.\n",
      "[55] Gray N, Stringer B, Bark G, et al. ‘When Ebola en-\n",
      "ters a home, a family, a community’: A qualitative study \n",
      "of population perspectives on Ebola control measures \n",
      "in rural and urban areas of Sierra Leone. PLoS Negl Trop \n",
      "Dis. 2018; 12 (6), e0006461.\n",
      "[56] Okware SI, Omaswa F, Talisuna A, et al. Managing \n",
      "Ebola from rural to urban slum settings: experiences \n",
      "from Uganda. Afr Health Sci. 2015; 15 (1), 312-321. \n",
      "[57] Caleo G, Duncombe J, Jephcott F, et al. The factors \n",
      "affecting household transmission dynamics and com-\n",
      "munity compliance with Ebola control measures: a \n",
      "mixed-methods study in a rural village in Sierra Leone. \n",
      "BMC Public Health. 2018; 18 (1), 248.\n",
      "[58] Baseler L, Chertow DS, Johnson KM, et al. The \n",
      "pathogenesis of Ebola virus disease. Ann Rev Pathol. \n",
      "2017; 12, 387-418.\n",
      "[59] Coltart CE, Lindsey B, Ghinai I, et al. The Ebola out-\n",
      "break, 2013–2016: old lessons for new epidemics. Philos \n",
      "Trans R Soc Lond B Biol Sci. 2017; 372 (1721), 20160297.\n",
      "[60] Swanson KC, Altare C, Wesseh CS, et al. (2018). \n",
      "Contact tracing performance during the Ebola epidem-\n",
      "ic in Liberia, 2014-2015. PLoS Negl Trop Dis. 2018; 12 (9), \n",
      "e0006762.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import PyPDF2\n",
    "from langchain.text_splitter import CharacterTextSplitter\n",
    "\n",
    "# Open the PDF file in binary mode ('rb')\n",
    "with open('EbolaVirus.pdf', 'rb') as file:\n",
    "    reader = PyPDF2.PdfReader(file)\n",
    "    full_text = ''\n",
    "    \n",
    "    # Extract text from each page of the PDF\n",
    "    for page_num in range(len(reader.pages)):\n",
    "        page = reader.pages[page_num]\n",
    "        full_text += page.extract_text()\n",
    "\n",
    "# Initialize the CharacterTextSplitter\n",
    "text_splitter = CharacterTextSplitter(chunk_size=1000, chunk_overlap=100)\n",
    "\n",
    "# Split the extracted text into chunks\n",
    "texts = text_splitter.split_text(full_text)\n",
    "\n",
    "# Display the chunked text\n",
    "for idx, chunk in enumerate(texts):\n",
    "    print(f\"Chunk {idx+1}:\\n{chunk}\\n\")\n"
   ]
  },
  {
   "cell_type": "raw",
   "id": "bf5a4223-8f57-4816-971d-d329a39b3109",
   "metadata": {},
   "source": [
    "Embeddings the text and storing in chroma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "19fbc13b-9156-48f6-aa23-855f845596bf",
   "metadata": {},
   "outputs": [],
   "source": [
    "#import chromadb"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "56da295d-5209-4afd-ae08-e3cf32df5449",
   "metadata": {},
   "outputs": [
    {
     "ename": "ImportError",
     "evalue": "Could not import chromadb python package. Please install it with `pip install chromadb`.",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mModuleNotFoundError\u001b[0m                       Traceback (most recent call last)",
      "File \u001b[1;32mD:\\ANACONDA\\Lib\\site-packages\\langchain_community\\vectorstores\\chroma.py:83\u001b[0m, in \u001b[0;36mChroma.__init__\u001b[1;34m(self, collection_name, embedding_function, persist_directory, client_settings, collection_metadata, client, relevance_score_fn)\u001b[0m\n\u001b[0;32m     82\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m---> 83\u001b[0m     \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mchromadb\u001b[39;00m\n\u001b[0;32m     84\u001b[0m     \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mchromadb\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mconfig\u001b[39;00m\n",
      "\u001b[1;31mModuleNotFoundError\u001b[0m: No module named 'chromadb'",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[1;31mImportError\u001b[0m                               Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[71], line 2\u001b[0m\n\u001b[0;32m      1\u001b[0m embeddings\u001b[38;5;241m=\u001b[39mOpenAIEmbeddings()\n\u001b[1;32m----> 2\u001b[0m db\u001b[38;5;241m=\u001b[39mChroma\u001b[38;5;241m.\u001b[39mfrom_texts(texts,embeddings)\n\u001b[0;32m      3\u001b[0m retriever\u001b[38;5;241m=\u001b[39mdb\u001b[38;5;241m.\u001b[39mas_retriever()\n",
      "File \u001b[1;32mD:\\ANACONDA\\Lib\\site-packages\\langchain_community\\vectorstores\\chroma.py:814\u001b[0m, in \u001b[0;36mChroma.from_texts\u001b[1;34m(cls, texts, embedding, metadatas, ids, collection_name, persist_directory, client_settings, client, collection_metadata, **kwargs)\u001b[0m\n\u001b[0;32m    781\u001b[0m \u001b[38;5;129m@classmethod\u001b[39m\n\u001b[0;32m    782\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mfrom_texts\u001b[39m(\n\u001b[0;32m    783\u001b[0m     \u001b[38;5;28mcls\u001b[39m: Type[Chroma],\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    793\u001b[0m     \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs: Any,\n\u001b[0;32m    794\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Chroma:\n\u001b[0;32m    795\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"Create a Chroma vectorstore from a raw documents.\u001b[39;00m\n\u001b[0;32m    796\u001b[0m \n\u001b[0;32m    797\u001b[0m \u001b[38;5;124;03m    If a persist_directory is specified, the collection will be persisted there.\u001b[39;00m\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    812\u001b[0m \u001b[38;5;124;03m        Chroma: Chroma vectorstore.\u001b[39;00m\n\u001b[0;32m    813\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[1;32m--> 814\u001b[0m     chroma_collection \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mcls\u001b[39m(\n\u001b[0;32m    815\u001b[0m         collection_name\u001b[38;5;241m=\u001b[39mcollection_name,\n\u001b[0;32m    816\u001b[0m         embedding_function\u001b[38;5;241m=\u001b[39membedding,\n\u001b[0;32m    817\u001b[0m         persist_directory\u001b[38;5;241m=\u001b[39mpersist_directory,\n\u001b[0;32m    818\u001b[0m         client_settings\u001b[38;5;241m=\u001b[39mclient_settings,\n\u001b[0;32m    819\u001b[0m         client\u001b[38;5;241m=\u001b[39mclient,\n\u001b[0;32m    820\u001b[0m         collection_metadata\u001b[38;5;241m=\u001b[39mcollection_metadata,\n\u001b[0;32m    821\u001b[0m         \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs,\n\u001b[0;32m    822\u001b[0m     )\n\u001b[0;32m    823\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m ids \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m    824\u001b[0m         ids \u001b[38;5;241m=\u001b[39m [\u001b[38;5;28mstr\u001b[39m(uuid\u001b[38;5;241m.\u001b[39muuid4()) \u001b[38;5;28;01mfor\u001b[39;00m _ \u001b[38;5;129;01min\u001b[39;00m texts]\n",
      "File \u001b[1;32mD:\\ANACONDA\\Lib\\site-packages\\langchain_core\\_api\\deprecation.py:215\u001b[0m, in \u001b[0;36mdeprecated.<locals>.deprecate.<locals>.finalize.<locals>.warn_if_direct_instance\u001b[1;34m(self, *args, **kwargs)\u001b[0m\n\u001b[0;32m    213\u001b[0m     warned \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m    214\u001b[0m     emit_warning()\n\u001b[1;32m--> 215\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m wrapped(\u001b[38;5;28mself\u001b[39m, \u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32mD:\\ANACONDA\\Lib\\site-packages\\langchain_community\\vectorstores\\chroma.py:86\u001b[0m, in \u001b[0;36mChroma.__init__\u001b[1;34m(self, collection_name, embedding_function, persist_directory, client_settings, collection_metadata, client, relevance_score_fn)\u001b[0m\n\u001b[0;32m     84\u001b[0m     \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mchromadb\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mconfig\u001b[39;00m\n\u001b[0;32m     85\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mImportError\u001b[39;00m:\n\u001b[1;32m---> 86\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mImportError\u001b[39;00m(\n\u001b[0;32m     87\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCould not import chromadb python package. \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m     88\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mPlease install it with `pip install chromadb`.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m     89\u001b[0m     )\n\u001b[0;32m     91\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m client \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m     92\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_client_settings \u001b[38;5;241m=\u001b[39m client_settings\n",
      "\u001b[1;31mImportError\u001b[0m: Could not import chromadb python package. Please install it with `pip install chromadb`."
     ]
    }
   ],
   "source": [
    "embeddings=OpenAIEmbeddings()\n",
    "db=Chroma.from_texts(texts,embeddings)\n",
    "retriever=db.as_retriever()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c1f5ee99-5dca-4c1c-81c9-1d601a153dc7",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
